FDA Advisory Committee supports approval of Gilead’s once-daily Quad single tablet regimen for HIV
11 May 2012 | By Gilead Sciences
Final FDA decision on the Quad anticipated late summer...
List view / Grid view
11 May 2012 | By Gilead Sciences
Final FDA decision on the Quad anticipated late summer...
11 May 2012 | By GlaxoSmithKline
The FDA has approved the New Drug Application for Fabior (tazarotene) Foam...
10 May 2012 | By Ballou PR
Company combines expertise in assay design with its powerful HTRF® technology...
10 May 2012 | By Novartis
Research on Lucentis® is highlighted in more than 200 abstracts this week at the 2012 ARVO annual meeting....
10 May 2012 | By Pfizer
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with David Simmons...
10 May 2012 | By Gilead Sciences
Vote to support approval of once-daily oral Truvada®...
10 May 2012 | By Bristol-Myers Squibb Company
Doug Manion to will make a formal presentation...
9 May 2012 | By Patheon
Patheon continues to implement its corporate transformation strategy across its commercial and pharmaceutical development services...
9 May 2012 | By BASF
BASF has announced the acquisition of Equateq Ltd...
9 May 2012 | By GlaxoSmithKline
GSK will not participate in Human Genome Sciences strategic alternatives...
9 May 2012 | By Biogen Idec
U.S. and EU regulatory authorities have accepted marketing applications for review...
9 May 2012 | By Pfizer
“We are pleased with the Committee’s positive evaluation..."
8 May 2012 | By kdm communications limited
Tecan recently invited customers from around Australasia to mark the inauguration of Tecan Australia as a fully owned Tecan subsidiary...
8 May 2012 | By H. Lundbeck A/S
Lu AA21004 may have positive effect on cognitive dysfunction in patients with major depressive disorders...
8 May 2012 | By Gilead Sciences
Webcast available through Gilead Corporate website...